Arecor Therapeutics PLC (AREC) — Cash Flow-to-Debt Ratio
Arecor Therapeutics PLC (AREC) has a Cash Flow-to-Debt Ratio of -0.48x as of June 2025, meaning its operating cash flow of GBX-1.14 Million could theoretically repay 0% of its total liabilities (GBX2.39 Million) in one year. See AREC working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Arecor Therapeutics PLC Cash Flow-to-Debt Ratio (2018–2024)
Historical debt coverage capacity for Arecor Therapeutics PLC across 8 annual periods. Also explore net asset growth rate of Arecor Therapeutics PLC to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Arecor Therapeutics PLC (2018–2024)
Year-by-year debt coverage analysis for Arecor Therapeutics PLC. For market capitalisation and broader financial context, see AREC market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (GBX) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -2.71x | GBX-9.15 Million | GBX3.37 Million | ▼ -171.8% |
| 2023 | -1.00x | GBX-5.84 Million | GBX5.85 Million | ▲ +60.1% |
| 2022 | -2.50x | GBX-10.78 Million | GBX4.31 Million | ▼ -8.9% |
| 2021 | -2.30x | GBX-5.45 Million | GBX2.37 Million | ▼ -334.4% |
| 2020 | -0.53x | GBX-1.86 Million | GBX3.51 Million | ▼ -26.6% |
| 2019 | -0.42x | GBX-458.80K | GBX1.10 Million | ▲ +79.4% |
| 2019 | -2.03x | GBX-2.50 Million | GBX1.23 Million | ▼ -475.0% |
| 2018 | -0.35x | GBX-492.57K | GBX1.40 Million | — |